US biopharmaceutical company Synaptogenix Inc (Nasdaq: SNPX) announced on Thursday that it has entered into a collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence.

The collaboration agreement involves pre-clinical testing of the firm's polyunsaturated fatty acid (PUFA) analogues as a treatment for spinal cord injury (SCI). The studies will compare the analogues with Bryostatin in SCI.

Synaptogenix also revealed that the US Patent and Trademark Office (USPTO) has issued US Patent No. 12,016,837 titled 'Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases' which covers its family of analogues.

Synaptogenix holds exclusive rights to its PUFA analogues pursuant to a licensing agreement with Cognitive Research Enterprises Inc (CRE), formerly known as the Blanchette Rockefeller Neurosciences Institute.